Abstract 5101
Background
Recent reports suggested gaps in knowledge and misperceptions regarding lung cancer (LC) in the general public and physicians respectively. We aimed to further investigate the topic.
Methods
From February 21st to March 22nd, 2019, two online surveys were led in parallel among French people (n = 6001) and physicians (GP, n = 273; pulmonologists, n = 97; oncologists, n = 67). Questions aimed to assess people’s knowledge about LC prevalence, severity, diagnosis, management and treatments, early screening, as well of social stigma, and also understandings from physicians about public perception.
Results
LC was ranked as the 2nd most feared cancer (n = 1980; 33%) and perceived as very or extremely serious by 96% of people (n = 5760). Half of French people (n = 3360) declared knowing at least one other risk factor than tobacco, and except for asbestos (n = 5220; 87%), other potential risk factors were subjects to low to moderate levels of belief. The general population ranked LC as the 3rd easiest cancer to diagnose among French people (n = 2220; 37%) and 57% (n = 3420) believed that diagnosis was made early after symptoms onset. The general population was not aware of the majority of the symptoms beside blood in the sputum and respiratory symptoms. LC was ranked only the 5th cancer (n = 1260; 21%) among those for which medical progress had been the most substantial, whereas physicians ranked it second (n = 201; 46%). Also the public was not aware of therapeutic progress as immunotherapy. Physicians tended to be more optimistic about actual treatment improvement than the public and for 90% of them (n = 393), systematic screening of at-risk population would have a significant impact on mortality data by LC.
Conclusions
Our study confirms the substantial gaps in LC knowledge from the general public and highlights several venues for improvement of communication and public awareness on LC in France.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
J. Cadranel: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Boerhinger Ingelheim; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: BMS; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. C. Chouaid: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: GSK; Advisory / Consultancy: Roche; Advisory / Consultancy: Sanofi Aventis; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Lilly; Advisory / Consultancy: Novartis; Advisory / Consultancy: Amgen. J.B. Stern: Speaker Bureau / Expert testimony, Fees for presentation in a Medtronic symposium which were donated to our association.: Medtronic. A. Vergnenegre: Advisory / Consultancy, Research grant / Funding (institution): Roche; Research grant / Funding (institution): Chugai; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Teva; Advisory / Consultancy, Research grant / Funding (institution): Lilly; Advisory / Consultancy: Clovis Oncology. C. Cortot: Full / Part-time employment: AstraZeneca. L. Guery: Full / Part-time employment: AstraZeneca. K. Belkhiria: Full / Part-time employment: AstraZeneca. I. De la Porte: Full / Part-time employment: AstraZeneca. M. Urbieta: Full / Part-time employment: AstraZeneca. M. Perol: Advisory / Consultancy: Novartis; Advisory / Consultancy: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract